Analyst firms · H.C. Wainwright · CBIO

H.C. Wainwright CBIO price target and rating history

Crescent Biopharma Inc. (CBIO) · Health Care

H.C. Wainwright rates Crescent Biopharma Inc. (CBIO) Buy with a $36 price target, as of its latest action on Oct 6, 2026. It has published 3 rating actions on CBIO since August 2025, including 1 upgrade and 1 downgrade. Across 3 firms with a CBIO price target in the last 12 months, the median target is $35. H.C. Wainwright's $36 is 3% above that.

Current rating
Buy
Price target
$36
Median target, all firms
$35
Actions on CBIO
3

H.C. Wainwright price target on CBIO

$36$31$252026
H.C. Wainwright price target on CBIO, each point a stated target, August 2025 to October 2026.

Every H.C. Wainwright rating on CBIO

How other firms rate CBIO

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
H.C. WainwrightBuy$36Oct 6, 2026
Piper SandlerOverweight$35Jan 28, 2026
GuggenheimBuy$35Jan 21, 2026

Questions about H.C. Wainwright and CBIO

What is H.C. Wainwright's price target for CBIO?
H.C. Wainwright's latest stated price target for Crescent Biopharma Inc. (CBIO) is $36, from its action on Oct 6, 2026.
What is H.C. Wainwright's rating on CBIO?
H.C. Wainwright rates CBIO Buy, a bullish rating, as of Oct 6, 2026.
When did H.C. Wainwright last change its view on CBIO?
On Oct 6, 2026, H.C. Wainwright upgrades to Buy from Neutral, price target $36.
How does H.C. Wainwright's CBIO target compare with other analysts?
Across 3 firms with a CBIO price target in the last 12 months, the median target is $35. H.C. Wainwright's $36 is 3% above that.

All H.C. Wainwright ratingsCBIO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.